// App-Quantinova.ai

P6-16-02 : Beta-adrenergic receptor blockers (BB) and increased progression free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/TRIO012 study

Researchers

Presenter

  • G Spera

Principal Investigators

  • R Fresco

  • H Fung

  • JRB Dyck

  • E Pituskin

  • I Patterson

  • L Aspeslet

  • JR Mackey

Medical Centers

  • Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada

  • Faculty of Nursing, University of Alberta, Edmonton, AB, Canada

  • University of Alberta, Edmonton, AB, Canada

Locations

  • Canada

Companies

  • Translational Resear

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Hypertension

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Ramucirumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved